Catalyst Pharmaceuticals Partners, Inc. (CPRX) stock: analyst price target and their real reliability
Live quote · data updated Oct 14, 2026
Catalyst Pharmaceuticals Partners, Inc. · Health Care · ref. ETF XLV · 52 calls
What the company does: Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
📈 Catalyst Pharmaceuticals Partners, Inc. (CPRX) stock price
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
0% recommend buying · 3 analysts
📊 JPI status : Catalyst Pharmaceuticals Partners, Inc. is no longer in our current JPI rankings, but appeared in the past (2024) — its upside may be behind it. See the stocks picked in 2024 →
🎯 CPRX price target & analyst consensus
The price target · all analysts combined (2 targets)
Highest target · 2 firms of 2$31.5
Median target · of 2 targets$31.5
Lowest target · 2 firms of 2$31.5
⭐ What the most reliable analysts say
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
The consensus · 3 ratings (last 6 months)
Strong Buy00%
Buy00%
Hold3100%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 CPRX price target all
All 52 calls, one by one, with our verdict on each firm.
→ See all 52 targets, analyst by analyst💡 The best analysts on CPRX most reliable
Their real reliability on CPRX, firm by firm: who was right, who was wrong.
→ See their reliability on CPRXAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Catalyst Pharmaceuticals Partners, Inc.? The JPI assistant answers using our backtest data.
🔎 Detailed analyses
✅ Historical analyst reliability on CPRX
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Aegis Capital | 0% | 0.0% | 3 |
| Piper Sandler ↗ | 0% | 0.0% | 4 |
| SunTrust Robinson Humphrey | 0% | 0.0% | 2 |
| Oppenheimer ↗ | 0% | 0.0% | 4 |
| Cantor Fitzgerald ↗ | 0% | 0.0% | 9 |
| Truist Securities ↗ | 0% | 0.0% | 8 |
| HC Wainwright & Co. ↗ | 0% | 0.0% | 14 |
| B of A Securities ↗ | 0% | 0.0% | 2 |
| Citigroup ↗ | 0% | 0.0% | 2 |
| Stephens & Co. ↗ | 0% | 0.0% | 2 |
📊 What $1,000 invested in Catalyst Pharmaceuticals Partners, Inc. would be worth › open the full page
In short — $1,000 invested in Catalyst Pharmaceuticals Partners, Inc. 10 years ago would be worth $12,853 today, i.e. +29%/yr on average. Best year: 2017 (+272%), worst: 2016 (-57%). Price performance, excluding dividends.
If I'd invested $1,000 in Catalyst Pharmaceuticals Partners, Inc.
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $1,509 | +51% |
| 3 years ago | $1,693 | +69% |
| 5 years ago | $9,428 | +843% |
Return by year (Catalyst Pharmaceuticals Partners, Inc.)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +35% | $1,349 (+35%) |
| 2025 | +12% | $1,509 (+51%) |
| 2024 | +24% | $1,873 (+87%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Catalyst Pharmaceuticals Partners, Inc.
Loading news…
📋 All analyst calls on CPRX
Filtered on — · ✕ show all
HC Wainwright & Co. ↗
May 28, 26
■ Neutral neutral · not a buy · 🎯$31.5
Price at call : $31.49 — gap to target +0%
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
in progress (365j)
matures : May 28, 27
matures : May 28, 27
■ Neutral neutral · not a buy · 🎯$31.5
Price at call : $31.49 — gap to target +0%
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 44.9% · -4.4% (107 calls)
in progress (365j)
matures : May 8, 27
matures : May 8, 27
Stephens & Co. ↗
May 7, 26
■ Equal-Weight neutral · not a buy
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 44.3% · +2.1% (88 calls)
in progress (365j)
matures : May 7, 27
matures : May 7, 27
▲ Buy · 🎯$35
Price at call : $31.49 — upside +11%
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 44.9% · -4.4% (107 calls)
in progress (365j)
matures : Mar 3, 27
matures : Mar 3, 27
▲ Buy · 🎯$33
Price at call : $31.49 — upside +5%
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 44.9% · -4.4% (107 calls)
in progress (365j)
matures : Nov 7, 26
matures : Nov 7, 26
▲ Outperform · 🎯$32
Price at call : $31.49 — upside +2%
Expected +2% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 38.1% · -2.9% (84 calls)
0.0%
stock +0% · XLV +5%
matured Mar 3, 26
HC Wainwright & Co. ↗
Feb 28, 25
▲ Buy · 🎯$35
Price at call : $31.49 — upside +11%
Expected +11% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV +6%
matured Feb 28, 26
Stephens & Co. ↗
Feb 27, 25
▲ Overweight · 🎯$33
Price at call : $31.49 — upside +5%
Expected +5% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 44.3% · +2.1% (88 calls)
0.0%
stock +0% · XLV +6%
matured Feb 27, 26
See the other 44 calls, newest to oldest
▲ Outperform · 🎯$28
Price at call : $31.49 — upside -11%
Expected -11% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 38.1% · -2.9% (84 calls)
0.0%
stock +0% · XLV +6%
matured Feb 4, 26
HC Wainwright & Co. ↗
Jan 10, 25
▲ Buy · 🎯$35
Price at call : $31.49 — upside +11%
Expected +11% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV +13%
matured Jan 10, 26
B of A Securities ↗
Jan 9, 25
▲ Buy · 🎯$30
Price at call : $31.49 — upside -5%
Expected -5% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 51.9% · +3.9% (156 calls)
0.0%
stock +0% · XLV +13%
matured Jan 9, 26
Stephens & Co. ↗
Nov 18, 24
▲ Overweight · 🎯$35
Price at call : $31.49 — upside +11%
Expected +11% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 44.3% · +2.1% (88 calls)
0.0%
stock +0% · XLV +8%
matured Nov 18, 25
Truist Securities ↗
Nov 11, 24
▲ Buy · 🎯$36
Price at call : $31.49 — upside +14%
Expected +14% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (8 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
0.0%
stock +0% · XLV +4%
matured Nov 11, 25
HC Wainwright & Co. ↗
Nov 8, 24
▲ Buy · 🎯$30
Price at call : $31.49 — upside -5%
Expected -5% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV -2%
matured Nov 8, 25
HC Wainwright & Co. ↗
Aug 12, 24
▲ Buy · 🎯$30
Price at call : $31.49 — upside -5%
Expected -5% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV -12%
matured Aug 12, 25
▲ Buy · 🎯$31
Price at call : $31.49 — upside -2%
Expected -2% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 44.9% · -4.4% (107 calls)
0.0%
stock +0% · XLV -13%
matured Aug 10, 25
Truist Securities ↗
Aug 9, 24
▲ Buy · 🎯$30
Price at call : $31.49 — upside -5%
Expected -5% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (8 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
0.0%
stock +0% · XLV -13%
matured Aug 9, 25
Oppenheimer ↗
Jun 6, 24
▲ Outperform · 🎯$29
Price at call : $31.49 — upside -8%
Expected -8% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (3 calls matureds) · 📊 on Health : 47.4% · +5.9% (95 calls)
0.0%
stock +0% · XLV -8%
matured Jun 6, 25
HC Wainwright & Co. ↗
Jun 3, 24
▲ Buy · 🎯$26
Price at call : $31.49 — upside -17%
Expected -17% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV -8%
matured Jun 3, 25
HC Wainwright & Co. ↗
May 10, 24
▲ Buy · 🎯$26
Price at call : $31.49 — upside -17%
Expected -17% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV -5%
matured May 10, 25
Oppenheimer ↗
Mar 27, 24
▲ Outperform · 🎯$29
Price at call : $31.49 — upside -8%
Expected -8% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (3 calls matureds) · 📊 on Health : 47.4% · +5.9% (95 calls)
0.0%
stock +0% · XLV -2%
matured Mar 27, 25
Cantor Fitzgerald ↗
Mar 22, 24
▲ Overweight · 🎯$34
Price at call : $31.49 — upside +8%
Expected +8% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (9 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
0.0%
stock +0% · XLV +1%
matured Mar 22, 25
Cantor Fitzgerald ↗
Mar 14, 24
▲ Overweight · 🎯$34
Price at call : $31.49 — upside +8%
Expected +8% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (9 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
0.0%
stock +0% · XLV +1%
matured Mar 14, 25
▲ Buy · 🎯$27
Price at call : $31.49 — upside -14%
Expected -14% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 44.9% · -4.4% (107 calls)
0.0%
stock +0% · XLV -1%
matured Mar 14, 25
B of A Securities ↗
Mar 7, 24
▲ Buy · 🎯$23
Price at call : $31.49 — upside -27%
Expected -27% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 51.9% · +3.9% (156 calls)
0.0%
stock +0% · XLV +1%
matured Mar 7, 25
Cantor Fitzgerald ↗
Mar 1, 24
▲ Overweight · 🎯$34
Price at call : $31.49 — upside +8%
Expected +8% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (9 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
0.0%
stock +0% · XLV +2%
matured Mar 1, 25
HC Wainwright & Co. ↗
Mar 1, 24
▲ Buy · 🎯$24
Price at call : $31.49 — upside -24%
Expected -24% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV +2%
matured Mar 1, 25
Oppenheimer ↗
Dec 21, 23
▲ Outperform · 🎯$30
Price at call : $31.49 — upside -5%
Expected -5% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (3 calls matureds) · 📊 on Health : 47.4% · +5.9% (95 calls)
0.0%
stock +0% · XLV +3%
matured Dec 20, 24
Cantor Fitzgerald ↗
Aug 22, 23
▲ Overweight · 🎯$27
Price at call : $31.49 — upside -14%
Expected -14% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (9 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
0.0%
stock +0% · XLV +16%
matured Aug 21, 24
Cantor Fitzgerald ↗
Aug 11, 23
▲ Overweight · 🎯$27
Price at call : $31.49 — upside -14%
Expected -14% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (9 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
0.0%
stock +0% · XLV +10%
matured Aug 10, 24
HC Wainwright & Co. ↗
Aug 11, 23
▲ Buy · 🎯$24
Price at call : $31.49 — upside -24%
Expected -24% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV +10%
matured Aug 10, 24
HC Wainwright & Co. ↗
Jul 21, 23
▲ Buy · 🎯$24
Price at call : $31.49 — upside -24%
Expected -24% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV +9%
matured Jul 20, 24
Truist Securities ↗
Jun 21, 23
▲ Buy · 🎯$24
Price at call : $31.49 — upside -24%
Expected -24% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (8 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
0.0%
stock +0% · XLV +11%
matured Jun 20, 24
Cantor Fitzgerald ↗
Jun 21, 23
▲ Overweight · 🎯$25
Price at call : $31.49 — upside -21%
Expected -21% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (9 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
0.0%
stock +0% · XLV +11%
matured Jun 20, 24
Truist Securities ↗
Jun 20, 23
▲ Buy · 🎯$24
Price at call : $31.49 — upside -24%
Expected -24% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (8 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
0.0%
stock +0% · XLV +11%
matured Jun 19, 24
HC Wainwright & Co. ↗
May 12, 23
▲ Buy · 🎯$24
Price at call : $31.49 — upside -24%
Expected -24% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV +9%
matured May 11, 24
HC Wainwright & Co. ↗
Mar 20, 23
▲ Buy · 🎯$24
Price at call : $31.49 — upside -24%
Expected -24% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV +15%
matured Mar 19, 24
Truist Securities ↗
Jan 19, 23
▲ Buy · 🎯$22
Price at call : $31.49 — upside -30%
Expected -30% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (8 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
0.0%
stock +0% · XLV +5%
matured Jan 19, 24
Truist Securities ↗
Dec 21, 22
▲ Buy · 🎯$18
Price at call : $31.49 — upside -43%
Expected -43% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (8 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
0.0%
stock +0% · XLV -1%
matured Dec 21, 23
HC Wainwright & Co. ↗
Dec 21, 22
▲ Buy · 🎯$24
Price at call : $31.49 — upside -24%
Expected -24% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV -1%
matured Dec 21, 23
Piper Sandler ↗
Dec 20, 22
▲ Overweight · 🎯$20
Price at call : $31.49 — upside -36%
Expected -36% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
0.0%
stock +0% · XLV -1%
matured Dec 20, 23
Roth Capital
Aug 24, 22
■ Neutral neutral · not a buy · 🎯$15.5
Price at call : $31.49 — gap to target -51%
🎯 on CPRX : 0% (1 call matured) · 📊 unranked overall
in progress (365j)
matures : Aug 24, 23
matures : Aug 24, 23
Truist Securities ↗
Aug 11, 22
▲ Buy · 🎯$17
Price at call : $31.49 — upside -46%
Expected -46% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (8 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
0.0%
stock +0% · XLV +2%
matured Aug 11, 23
HC Wainwright & Co. ↗
Aug 11, 22
▲ Buy · 🎯$18
Price at call : $31.49 — upside -43%
Expected -43% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV +3%
matured Aug 11, 23
HC Wainwright & Co. ↗
Feb 8, 22
▲ Buy · 🎯$12
Price at call : $31.49 — upside -62%
Expected -62% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (14 calls matureds) · 📊 on Health : 57.4% · +25.1% (329 calls)
0.0%
stock +0% · XLV -1%
matured Feb 8, 23
Roth Capital
Mar 18, 21
▲ Buy · 🎯$7
Price at call : $31.49 — upside -78%
Expected -78% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (1 call matured) · 📊 unranked overall
0.0%
stock +0% · XLV +19%
matured Mar 18, 22
Truist Securities ↗
Aug 12, 20
▲ Buy · 🎯$8
Price at call : $31.49 — upside -75%
Expected -75% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (8 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
0.0%
stock +0% · XLV +24%
matured Aug 12, 21
SunTrust Robinson Humphrey
May 13, 20
▲ Buy · 🎯$10
Price at call : $31.49 — upside -68%
Expected -68% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (1 call matured) · 📊 unranked overall
0.0%
stock +0% · XLV +25%
matured May 13, 21
Cantor Fitzgerald ↗
Feb 14, 20
▲ Overweight · 🎯$12
Price at call : $31.49 — upside -62%
Expected -62% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (9 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
0.0%
stock +0% · XLV +12%
matured Feb 13, 21
Piper Sandler ↗
Dec 13, 18
▲ Overweight · 🎯$7.5
Price at call : $31.49 — upside -76%
Expected -76% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (2 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
0.0%
stock +0% · XLV +15%
matured Dec 13, 19
Cantor Fitzgerald ↗
Nov 29, 18
▲ Overweight · 🎯$8
Price at call : $31.49 — upside -75%
Expected -75% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (9 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
0.0%
stock +0% · XLV +3%
matured Nov 29, 19
Cantor Fitzgerald ↗
Sep 21, 18
▲ Overweight · 🎯$8
Price at call : $31.49 — upside -75%
Expected -75% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on CPRX : 0% (9 calls matureds) · 📊 on Health : 50% · +13.4% (168 calls)
0.0%
stock +0% · XLV -3%
matured Sep 21, 19
Frequently asked questions
Should I buy Catalyst Pharmaceuticals Partners, Inc. stock?
This isn't buy advice. For Catalyst Pharmaceuticals Partners, Inc., the analyst consensus is "Hold", with an average price target of $31.50. What matters is their past reliability on this stock: the most reliable one is right 0% of the time (3 calls tracked on Catalyst Pharmaceuticals Partners, Inc.). We show the numbers — you decide.
Is it too late to buy Catalyst Pharmaceuticals Partners, Inc.? How high can it go?
The most bullish analyst target on Catalyst Pharmaceuticals Partners, Inc. is $31.50; the average is $31.50. That's the upside they see. Check how reliable those analysts have actually been on Catalyst Pharmaceuticals Partners, Inc. on our site before trusting it.
Is Catalyst Pharmaceuticals Partners, Inc. still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 11 analysts have a real record on Catalyst Pharmaceuticals Partners, Inc., the best hitting 0% over 3 calls. Current consensus: "Hold". Make your call on data, not noise.
What has Catalyst Pharmaceuticals Partners, Inc.'s past performance been?
Historical returns and a "how much if I had invested" calculator: CPRX performance & returns.
BIIB 
VRTX 
REGN 
UNH 
EW 
SRPT 
VEEV 
BSX